Third Quarter Revenue Forecast for IDYA issued by Leerink Partnrs

IDEAYA Biosciences, Inc. (NASDAQ: IDYA – Free report) – Equities research analysts at Leerink Partnrs reduced their Q3 2024 EPS estimates for IDEAYA Biosciences in a report issued on Tuesday, October 22nd. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.71) per share for the quarter, down from their prior forecast of ($0.70). The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences’ Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($2.64) EPS, FY2025 earnings at ($3.28) EPS, FY2026 earnings at ($3.28) EPS. at ($7), FY27 Revenue at ($7.27) and 2028 Earnings at ($0.21) EPS.

IDEAYA Biosciences (NASDAQ: IDYA – Get a free report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.14). During the same period in the previous year, the company posted ($0.50) earnings per share.

Several other research analysts have also recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Stifel Nicolaus boosted their price objective on IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, September 10th. Oppenheimer decreased their price objective on IDEAYA Biosciences from $60.00 to $53.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Lifesci Capital upgraded shares of IDEAYA Biosciences to a “strong-buy” rating in a report on Monday, July 29th. Finally, Mizuho assumed coverage on IDEAYA Biosciences in a research report on Monday, July 8th. They set an “outperform” rating and a $50.00 price objective for the company. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. IDEAYA Biosciences currently has a consensus rating of “Buy” and an average price target of $55.45, according to MarketBeat.com.

See the latest stock report on IDYA

IDEAYA Biosciences stocks up 0.3%

Actions of IDEAYA Biosciences stock opened at $29.30 on Thursday. IDEAYA Biosciences has a one year low of $25.22 and a one year high of $47.74. The company’s 50-day simple moving average is $34.32, and its two-hundred-day simple moving average is $37.54.

Institutional investors intervene on IDEAYA Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Allworth Financial LP raised its stake in IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 800 shares in the last quarter. Quest Partners LLC bought a new stake in IDEAYA Biosciences in the second quarter valued at approximately $41,000. Covestor Ltd raised its position in IDEAYA Biosciences by 9,225.0% in the first quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after buying an additional 1,107 shares during the last quarter. Comerica Bank boosted its stake in IDEAYA Biosciences by 723.5% in the first quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after acquiring an additional 1,324 shares during the period. Finally, JTC Employer Solutions Trustee Ltd acquired a new stake in shares of IDEAYA Biosciences in the 1st quarter valued at about $67,000. Institutional investors own 98.29% of the company’s shares.

IDEAYA Biosciences Company Profile

(Get a free report)

IDEAYA Biosciences, Inc, a precision medicine oncology company focused on synthetic lethality, discovers and develops targeted therapies for selected patient populations using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in phase 2/3 clinical trials for genetically defined cancers with GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in phase 1/2 clinical trials for patients with solid tumors with methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD) and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Featured stories

Get news and reviews for IDEAYA Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IDEAYA Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.